News Search Results
Oct 29, 2025, 21:00 ET ArkBio Initiates Phase II Clinical Trial of AK0610, a Preventive Monoclonal Antibody for Respiratory Syncytial Virus Infection
including Roche, Genentech, the Scripps Research Institute, the Institute of Microbiology of Chinese Academy of Sciences, domestic and international biotechnology companies, as well as venture capital institutions. For more information, please visit:
More news about: Arkbio
Oct 29, 2025, 21:00 ET ArkBio Initiates Phase II Clinical Trial of AK0610, a Preventive Monoclonal Antibody for Respiratory Syncytial Virus Infection
including Roche, Genentech, the Scripps Research Institute, the Institute of Microbiology of Chinese Academy of Sciences, domestic and international biotechnology companies, as well as venture capital institutions. For more information, please visit:
More news about: Arkbio
Oct 29, 2025, 20:30 ET Latham & Watkins Names New Partners and Counsel
data-focused transactions and matters in the healthcare and life sciences industry, including emerging and established multinational pharmaceutical, biotechnology, digital health, and medical technology companies and their investors.
More news about: Latham & Watkins LLP
Oct 29, 2025, 20:30 ET Latham & Watkins Names New Partners and Counsel
data-focused transactions and matters in the healthcare and life sciences industry, including emerging and established multinational pharmaceutical, biotechnology, digital health, and medical technology companies and their investors.
More news about: Latham & Watkins LLP
Oct 29, 2025, 20:10 ET Ascletis Selects a Best-in-Class Once-Monthly Subcutaneously Administered Amylin Receptor Agonist, ASC36, for Clinical Development
About Ascletis Pharma Inc. Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases.
More news about: Ascletis Pharma Inc.
Oct 29, 2025, 16:56 ET MIT Technology Review and the Financial Times form strategic editorial partnership to explore the global impact of artificial intelligence
MIT Technology Review is the trusted global voice on the impact of emerging technologies-from artificial intelligence and biotechnology to climate and energy. Through award-winning journalism, expert analysis, and signature franchises such as 10 Breakthrough Technologies and Innovators
More news about: MIT Technology Review
Oct 29, 2025, 16:38 ET Kyowa Hakko Bio Evolves: Kyowa Hakko Bio Italia Named European Gateway with Expanded EMEA Role and Health Science Focus
shared value. Kyowa Hakko Bio Co. LtdKyowa Hakko Bio Co., Ltd. is a global leader in biotechnology and health science, serving as a core company within Kirin Holdings' Health Science domain. With over 75 years of fermentation expertise and a commitment
More news about: Kyowa Hakko U.S.A
Oct 29, 2025, 16:20 ET Bio-Process Systems Alliance Announces Locations for the 2026 & 2027 BPSA International Single-Use Summits
Chris Clark, Executive Director of BPSA. "These locations were selected based on member and attendee feedback. Boston is a leading global hub for biotechnology innovation, while Washington, DC keeps us closely connected to regulatory agencies and policy leaders. Both venues will help us foster collaboration
More news about: Bio-Process Systems Alliance (BPSA)
Oct 29, 2025, 16:01 ET AMGEN ANNOUNCES WEBCAST OF 2025 THIRD QUARTER FINANCIAL RESULTS
to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing
More news about: Amgen
Oct 29, 2025, 14:58 ET Sepsis Diagnostics Market to Reach USD 1,790.9 million by 2032, Growing At An 7.85% CAGR - Credence Research
highly competitive and innovative field, populated by a mix of large, diversified in-vitro diagnostics (IVD) corporations and smaller, specialized biotechnology firms. Industry giants such as bioMérieux SA, Becton, Dickinson and Company (BD), Abbott Laboratories, Danaher Corporation (through its subsidiaries
More news about: Credence Research Inc.
Oct 29, 2025, 14:40 ET Profiling Biology at Scale with DRUG-seq: From Mechanisms to Safety, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Oct 29, 2025, 14:30 ET Accelerating Radiopharmaceutical Therapy with Translational Tools, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Oct 29, 2025, 14:30 ET Boost Participant Recruitment with Precision Feasibility and RWD, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Oct 29, 2025, 14:22 ET Digital Pathology Market Size to Surpass USD 6.55 Billion by 2035, Rising at a CAGR of 17.15% | Report by Vantage Market Research
imaging resolution and workflow efficiency. Forge Strategic Alliances Across the Diagnostic Value Chain – Partner with biotechnology companies, hospitals, and AI developers to validate digital workflows, integrate automated systems, and accelerate adoption in high-growth healthcare
More news about: Vantage Market Research
Oct 29, 2025, 12:05 ET Valthos Raises $30M from OpenAI, Lux Capital, Founders Fund to Build Next-Generation Biodefense
Kathleen McMahon, former head of Palantir's Life Sciences division, Valthos brings together a team spanning software engineering, ML development, and biotechnology. The founding team consists of engineers from Palantir and DeepMind, and computational biologists from Stanford's Arc Institute and MIT's Broad
More news about: Valthos Inc
Oct 29, 2025, 10:30 ET Iris Ventures Makes Multimillion-Dollar Investment in Goddess Maintenance Co., Pioneering a New Era of "Bioprotection" in Hair Care
breakthrough hair care brands Olaplex and K18, joined forces with sisters Vesler and Mason to create a next-generation professional system grounded in biotechnology. At the heart of the brand is the Goddess Molecule, developed in partnership with biomaterials innovation leader, Bolt. Inspired
More news about: Goddess Maintenance Co.
Oct 29, 2025, 10:30 ET Lilly announces more than $1.2 billion investment in Puerto Rico facility to boost oral medicine manufacturing capacity in the United States
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Oct 29, 2025, 09:00 ET FDA Accepts BioMarin's PALYNZIQ® (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria
About BioMarin BioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based
More news about: BioMarin Pharmaceutical Inc.
Oct 29, 2025, 08:39 ET CounterX Therapeutics Announces Publication Demonstrating CTRX-101, an Anti-Fentanyl Monoclonal Antibody Therapy, Reverses Fentanyl-Induced Overdose in Preclinical Model
SEATTLE, Oct. 29, 2025 /PRNewswire/ -- CounterX Therapeutics, Inc., a biotechnology company focused on developing novel antibody therapeutics and vaccines to address opioid overdose and dependence, today announced the publication
More news about: CounterX Therapeutics
Oct 29, 2025, 08:34 ET GeneVentiv Therapeutics Announces Positive FDA INTERACT Feedback Supporting Advancement of GENV-HEM Gene Therapy for Hemophilia A with or without Inhibitors
RALEIGH, N.C., Oct. 29, 2025 /PRNewswire/ -- GeneVentiv Therapeutics, Inc., a privately held biotechnology company developing one-time gene therapies for rare and inherited diseases, today announced that it held a successful INTERACT meeting with the
More news about: GeneVentiv Therapeutics
Oct 29, 2025, 08:33 ET GlycoNex Announces Last Patient Dosed in Phase 3 Trial of SPD8, a Denosumab Biosimilar for Osteoporosis
commercialization collaborations. About GlycoNex Inc. GlycoNex Inc. is a clinical-stage biotechnology company focused on the development of glycan-directed cancer immunotherapies that effectively inhibit tumor growth while minimizing side effects.
More news about: GlycoNex, Inc.
Oct 29, 2025, 08:30 ET Miami Biotech Collective Introduces Board of Advisors and Women's Leadership Council to Shape South Florida's Biotech Future
companies, careers, and innovation thrive. Together, alongside local and statewide partners, we are positioning South Florida as a leading hub for biotechnology. Learn more at
More news about: Miami Biotech Collective
Oct 29, 2025, 08:05 ET Rigel Announces Conference Call and Webcast to Report Third Quarter 2025 Financial Results and Business Update
About Rigel Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders
More news about: Rigel Pharmaceuticals, Inc.
Oct 29, 2025, 08:00 ET Numerion Labs Publishes Breakthrough AI Research on Ultra-Fast Screening of Hyper-Scalable Virtual Libraries with NVIDIA
targets, including kinases, GPCRs, proteases and nuclear receptors. These advances have the potential to fundamentally reshape how pharmaceutical and biotechnology companies approach hit discovery by enabling comprehensive, real-time exploration of chemical space. This, in turn, can accelerate progression to
More news about: Numerion Labs
Oct 29, 2025, 07:05 ET REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2025 Financial Results and Operational Highlights
advised to join 15 minutes prior to the start time. ABOUT REGENXBIO Inc. REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field
More news about: REGENXBIO Inc.